7alpha-hydroxycholesterol : The 7alpha-hydroxy derivative of cholesterol. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 107722 |
| CHEMBL ID | 497207 |
| CHEBI ID | 17500 |
| SCHEMBL ID | 281941 |
| MeSH ID | M0058248 |
| Synonym |
|---|
| 7alpha-hydroxy-cholesterol |
| CHEBI:17500 , |
| 7 alpha-hydroxycholesterol |
| cholest-5-en-3beta,7alpha-diol |
| LMST01010013 |
| 566-26-7 |
| 7alpha-hydroxycholesterol |
| C03594 |
| cholest-5-ene-3beta,7alpha-diol |
| 5-cholesten-3beta,7alpha-diol |
| 7-hydroxycholesterol |
| 7alpha-cholesterol |
| 7|a-hydroxy cholesterol |
| CHEMBL497207 |
| (3s,7s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-3,7-diol |
| unii-95d0i22i0v |
| 7-alpha-hydroxycholesterol |
| 95d0i22i0v , |
| cholest-5-ene-3,7-diol, (3beta,7alpha)- |
| 7|a-hydroxycholesterol |
| gtpl4351 |
| 7-alpha-ohc |
| cholest-5-ene-3,7-diol, (3.beta.,7.alpha.)- |
| 7.alpha.-hydroxycholesterol |
| cholest-5-ene-3.beta.,7.alpha.-diol |
| 7.alpha.-hydroxycholest-5-en-3.beta.-ol |
| SCHEMBL281941 |
| 7alpha-hydroxy cholesterol |
| 5jk , |
| 7-a-hydroxycholesterol |
| AS-60936 |
| (3beta,7alpha,9beta,14beta)-cholest-5-ene-3,7-diol |
| 5-cholesten-3-beta,7-alpha-diol |
| 7-alpha-hydroxy cholesterol |
| DTXSID40903965 |
| CS-0111004 |
| HY-N7264 |
| Q155744 |
| 5-cholesten-3-beta, 7-alpha-diol |
| 7 alpha -hydroxy cholesterol |
| (3beta,7alpha)-cholest-5-ene-3,7-diol |
| 7alpha-hydroxycholest-5-en-3betaol |
| AKOS037645470 |
| 7(c) paragraph sign-hydroxycholesterol |
| 7?-hydroxy cholesterol |
| A937396 |
| PD046603 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " In general, the oxysterols were more toxic to cancer cells and a set of compounds (9, 14, 21, 28, 45) with very high selectivity was identified." | ( Selective cytotoxicity of oxysterols through structural modulation on rings A and B. Synthesis, in vitro evaluation, and SAR. Carvalho, JF; Moreira, JN; Sá E Melo, ML; Silva, MM; Simões, S, 2011) | 0.37 |
| Role | Description |
|---|---|
| mouse metabolite | Any mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus). |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| 7alpha-hydroxy steroid | A 7-hydroxy steroid in which the hydroxy group at position 7 has an alpha-configuration. |
| oxysterol | An oxygenated derivative of cholesterol |
| 3beta-hydroxy-Delta(5)-steroid | Any 3beta-hydroxy-steroid that contains a double bond between positions 5 and 6. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.84) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||